Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies
Award amount
$443,588Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SILVER LAKE RESEARCH CORPORATION
- Proposal award date
- 2015-08-01
- Contract end date
- 2018-01-31
- UEI
- C9FZMJCTQFP4
- Solicitation number
- DK14-008
- Topic code
- 200
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease
- EAP-DERIVED MONOCLONAL ANTIBODIES FOR ""WISH LIST"" HAMSTER IMMUNE TARGETS INVOLVED IN CELL ACTIVATION.
- EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.
- EAP-Derived Monoclonal Antibodies or Phenotyping Immune Cells of Animal Models of Disease
- Rapid LFIA blood test for SCD using highly specific monoclonal antibodies
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
12 SBIR/STTR records share this UEI (2006–2023). Reported award amounts total $9,165,947. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Environmental Protection Agency